UCB Pharma GmbH secures contract for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient bimekizumab, ATC L04AC21 for the period 01102024 - 30092026

Germany, Oct. 2 -- Germany based UCB Pharma GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient bimekizumab, ATC L04AC21 for the period 01102024 - 30092026 . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....